Sophia Genetics SA

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on August 12, 2026 for $7.52 per share.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 4,000 shares of common stock on August 13, 2026 for $7.52 per share.

Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on August 7, 2026 for $7.60 per share.

Jurgi Camblong, Executive Chairman and a Director of SOPHiA GENETICS SA, sold 28,500 shares of common stock on August 7, 2026.

Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 20,000 shares of common stock on August 5, 2026.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of common stock on July 27, 2026 for $5.66 per share.

Balderton Capital VI, S.L.P. has filed an Amendment No. 3 to its Schedule 13G, reporting beneficial ownership of 4.9% of Sophia Genetics SA's Ordinary Shares.

Akre Capital Management, LLC, along with Braddock Partners Offshore, LP and Braddock Capital Offshore, LLC, has disclosed a passive beneficial ownership of 5.6% in SOPHiA GENETICS SA, totaling 3,719,140 ordinary shares.